Carlsmed, Inc. (CARL) Price & Analysis

Compare

51 Followers

CARL Stock Chart & Stats

$12.87

Market closed

$12.87

Day’s Range― - ―

52-Week Range$11.45 - $17.19

Previous CloseN/A

VolumeN/A

Average Volume (3M)74.22K

Market Cap

$342.25M

Enterprise Value$184.52M

Total Cash (Recent Filing)$115.37M

Total Debt (Recent Filing)$17.61M

Price to Earnings (P/E)―

Beta3.07

Next Earnings

Feb 19, 2026

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding26,592,909

10 Day Avg. Volume67,597

30 Day Avg. Volume74,216

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)-3.40

Price to Sales (P/S)8.84

P/FCF Ratio-9.36

Enterprise Value/Market Cap0.54

Enterprise Value/Revenue4.12

Enterprise Value/Gross Profit5.52

Enterprise Value/Ebitda-7.67

Forecast

1Y Price Target

$20.50

Price Target Upside59.29% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.62

Revenue Forecast (FY)$69.82M

Bulls Say, Bears Say

Bulls Say

Market AdoptionSurgeon adoption likely source of upside as spine surgeons favor new tech and feedback has been positive.

Revenue GrowthCARL is confident in its full year revenue guide due to strong new surgeon adoption and scheduled procedure volume visibility.

Technological AdvancementsCarlsmed’s Aprevo Technology Platform is pioneering a new standard of care in spine fusion surgery with custom 3D printed interbody implants and an AI enabled surgical planning software.

Bears Say

Carlsmed, Inc. News

Carlsmed price target raised to $20 from $19 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Carlsmed (CARL) to $20 from $19 and keeps a Buy...

3d ago

CARL

Carlsmed publishes new retrospective cohort study in Global Spine

Carlsmed (CARL) announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D...

5d ago

CARL

Carlsmed announces U.S. launch of its aprevo Technology Platform

Carlsmed (CARL) announced the U.S. commercial launch of its aprevo Technology Platform for cervical fusion surgeries. Surgeons involved...

1M ago

CARL

Carlsmed price target raised to $24 from $21 at BTIG

BTIG analyst Ryan Zimmerman raised the firm’s price target on Carlsmed (CARL) to $24 from $21 and keeps...

2M ago

CARL

Carlsmed Reports Strong Q3 Growth and Raises Guidance

Carlsmed, Inc. ( ($CARL) ) has released its Q3 earnings. Here is a breakdown of the information Carlsmed,...

2M ago

CARL

Carlsmed raises FY25 revenue view to $49M-$50M from $45.5M-$47.5M

Consensus $46.52M. The company said, “Revenue for the full year 2025 is expected to be in the range...

2M ago

CARL

Carlsmed reports Q3 EPS (40c), consensus (49c)

Reports Q3 revenue $13.07M, consensus $11.38M. “We delivered another strong quarter with 98% revenue growth year-over-year, expanded gross...

2M ago

CARL

Carlsmed Secures $60 Million Credit Facility Amendment

Carlsmed, Inc. ( ($CARL) ) has shared an update. On October 29, 2025, Carlsmed, Inc. amended its Loan...

2M ago

CARL

Carlsmed appoints Jennifer Kamocsay as CLO, secretary

Carlsmed (CARL) announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay...

3M ago

CARL

Carlsmed announces inclusion in Russell 2000 Index

Carlsmed (CARL) announced that effective after market close on September 22, 2025, it has been added to the...

4M ago

CARL

Here’s Goldman Sachs’ Next S&P 500 Target — Plus 2 Top Stock Picks

The stock markets are at record highs, having shown a solid recovery from their sharp losses in April....

4M ago

BRZE

CARL

Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating

BTIG analyst Ryan Zimmerman has maintained their bullish stance on CARL stock, giving a Buy rating today. Ryan...

5M ago

CARL

Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch

Analyst Travis Steed from Bank of America Securities reiterated a Buy rating on Carlsmed, Inc. and keeping the...

5M ago

CARL

Carlsmed Reports Strong Growth in Q2 2025 Earnings

Carlsmed, Inc. ( ($CARL) ) has released its Q2 earnings. Here is a breakdown of the information Carlsmed,...

5M ago

CARL

CARL FAQ

What was Carlsmed, Inc.’s price range in the past 12 months?

Carlsmed, Inc. lowest stock price was $11.45 and its highest was $17.19 in the past 12 months.

What is Carlsmed, Inc.’s market cap?

Carlsmed, Inc.’s market cap is $342.25M.

When is Carlsmed, Inc.’s upcoming earnings report date?

Carlsmed, Inc.’s upcoming earnings report date is Feb 19, 2026 which is in 38 days.

How were Carlsmed, Inc.’s earnings last quarter?

Carlsmed, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.482 by $0.082.

Is Carlsmed, Inc. overvalued?

According to Wall Street analysts Carlsmed, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Carlsmed, Inc. pay dividends?

Carlsmed, Inc. does not currently pay dividends.

What is Carlsmed, Inc.’s EPS estimate?

Carlsmed, Inc.’s EPS estimate is -0.41.

How many shares outstanding does Carlsmed, Inc. have?

Carlsmed, Inc. has 26,592,909 shares outstanding.

What happened to Carlsmed, Inc.’s price movement after its last earnings report?

Carlsmed, Inc. reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.482. Following the earnings report the stock price went up 14.886%.

Which hedge fund is a major shareholder of Carlsmed, Inc.?

Currently, no hedge funds are holding shares in CARL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Carlsmed, Inc. Stock Smart Score

Neutral

Company Description

Carlsmed, Inc.

Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. Its product includes aprevo, a medical platform that makes surgical plans and devices tailored to the precise medical situation of every individual patient. It provides New Technology Add-On Payment (NTAP) reimbursement. The company was incorporated in 2018 and is based in Carlsbad, California.

Carlsmed, Inc. (CARL) Earnings & Revenues

Historic Earnings Reports

CARL Earnings Call

Q3 2025

0:00 / 0:00

CARL Stock 12 Month Forecast

Average Price Target

$20.50

▲(59.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","18":"$18","25":"$25","14.5":"$14.5","21.5":"$21.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,14.5,18,21.5,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.99,15.683076923076923,16.376153846153848,17.06923076923077,17.762307692307694,18.455384615384617,19.14846153846154,19.841538461538462,20.534615384615385,21.22769230769231,21.92076923076923,22.613846153846154,23.306923076923077,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.99,15.413846153846155,15.837692307692308,16.26153846153846,16.685384615384617,17.10923076923077,17.533076923076923,17.956923076923076,18.380769230769232,18.804615384615385,19.228461538461538,19.652307692307694,20.076153846153847,{"y":20.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.99,15.221538461538461,15.453076923076923,15.684615384615384,15.916153846153847,16.147692307692306,16.37923076923077,16.610769230769233,16.842307692307692,17.073846153846155,17.305384615384614,17.536923076923078,17.768461538461537,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.45,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.89,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >